Cadila

Transitional opportunity due to Revlimid helped this quarter, though remaining quarters may not witness a similar contribution. Hence, margins are likely to moderate.

Zydus Lifesciences: Why we still remain positive

Annual sales traction from Revlimid is decent and it is likely to stay so till 2026. The management is also positive about the product pipeline

Zydus Lifesciences: Time to book profit, post strong rally over a year?

Management is aiming for a single-digit growth in the US market for FY24 on the back of launches from the Moraiya facility.

Zydus Lifesciences: Transdermal opportunity to unfold

The US and domestic formulation businesses help the pharma company to do well in Q3

Cadila in talks with Centre, states for supply of three-dose rabies vaccine

The new vaccine cuts short the duration of treatment and saves lives by making compliance easier.

Zydus Lifesciences: Nephrology, biosimilar scope takes focus

Valuation reasonable on the back of traction in branded business

Cadila Pharma launches drug to treat high LDL-cholesterol

Cadila Pharmaceuticals said it has launched a drug for the treatment of high LDL-cholesterol or bad cholesterol which can lead to serious life-threatening heart complications due to blockage in blood vessels.

Cadila: Biosimilars, oncology portfolio hold promise for medium term

The Moraiya plant’s pending USFDA approval is crucial for Cadila’s US ambition

Cadila: Unfolding vaccine opportunity can offset US headwinds

For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables

Cadila: More a COVID hedge in the near term

Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility

Herd Immunity Part 2: Is the race a sprint or a marathon?

In terms of Fauci’s estimated threshold (70 percent) for herd immunity, India might reach that goal by mid-November.

Deregulation of vaccine rollout: What it means for pharma players

Dr Reddy’s, Gland Pharma, Strides, Cadila, Aurobindo are some of the names that merit a close watch as operating leverage plays out

Weekly Tactical Pick | Cadila Healthcare

COVID opportunity and traction in complex pharma pipeline are big positives for Cadila

Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?

Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan

Net Sales are expected to increase by 2.5 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 3,844 crore, according to Sharekhan.

What ‘second wave’ means for investors in Indian pharma

Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

Cadila: COVID vaccine to be the key differentiator in the near term

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion

COVID Vaccine: The opportunities for investors - Part I

Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

Cadila Q2: Strong operational show backed by traction in COVID portfolio

In the next three years, Cadila plans to launch 45 injectables, which are expected to generate revenue of USD 150-200 million at peak

Zydus Cadila gets USFDA nod to market generic antihistamine tablets

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Meclizine hydrochloride tablets in the strengths of 12.5 mg and 25 mg, the company said in a statement.

Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.

Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan

Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.

Buy Cadila; target of Rs 540: Axis Direct

Axis Direct is bullish on Cadila has recommended buy rating on the stock with a target price of Rs 540 in its research report dated August 18, 2017.